# A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

> **NCT05559580** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 214 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **DRUG:** Avenciguat (BI 685509)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05559580
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-13
- **Primary completion:** 2025-10-22
- **Final completion:** 2026-01-30
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559580, "A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05559580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*